1st Hepatitis E virus network (HEVnet) meeting
The key objective of this meeting is to verify the rationale and objectives of molecular typing for surveillance of hepatitis E virus (HEV) through the hepatitis E network (HEVnet). The workshop will review HEVnet as a tool for molecular surveillance of HEV in Europe.
ECDC: around 9 million Europeans are affected by chronic hepatitis B or C
An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million (3.9) with chronic hepatitis C infection. However, large numbers of them are not even aware of their infection as they have not yet been tested and diagnosed.
ECDC report: 10-fold increase of hepatitis E cases in the EU/EEA between 2005 and 2015
The incidence of hepatitis E virus (HEV) infection has been steadily increasing across the countries of the European Union and European Economic Area (EU/EEA) with 21 081 cases reported in the EU/EEA over the last decade.
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial
The efficacy and safety of a new recombinant hepatitis E vaccine (HEV 239) manufactured in China was assessed in a randomised, double-blind placebo-controlled phase 3 trial among 97,356 healthy individuals aged 16-65 years in Jiangsu province, China.